ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
Dow Jones
40.003,59
0,34%
Euro vs US Dollar
1,08945
-0,01%
Bitcoin
67.089,63
0,01%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. CohBar Inc (CWBR)

  7. CohBar Inc (CWBR) News

CWBR

CohBar (CWBR)

CohBar Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:CWBR
DatumZeitQuelleÜberschriftSymbolFirma
28/11/202300h05Business WireCohBar, Inc.: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (Form 8-K)NASDAQ:CWBRCohBar Inc
27/11/202323h21Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CWBRCohBar Inc
13/11/202315h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CWBRCohBar Inc
01/11/202314h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CWBRCohBar Inc
25/10/202315h01Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:CWBRCohBar Inc
25/10/202315h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CWBRCohBar Inc
06/10/202322h13Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:CWBRCohBar Inc
06/10/202322h11Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:CWBRCohBar Inc
04/10/202315h14Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:CWBRCohBar Inc
04/10/202315h12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CWBRCohBar Inc
13/09/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CWBRCohBar Inc
12/09/202322h47Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:CWBRCohBar Inc
12/09/202319h44Edgar (US Regulatory)Form S-4/A - Registration of securities, business combinations: [Amend]NASDAQ:CWBRCohBar Inc
14/08/202322h07Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CWBRCohBar Inc
14/08/202322h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CWBRCohBar Inc
14/08/202322h01GlobeNewswire Inc.CohBar Reports Second Quarter 2023 Financial ResultsNASDAQ:CWBRCohBar Inc
10/08/202323h30Edgar (US Regulatory)Form S-4/A - Registration of securities, business combinations: [Amend]NASDAQ:CWBRCohBar Inc
05/06/202314h05GlobeNewswire Inc.Morphogenesis, Inc. and CohBar, Inc. Announce Positive Results from Phase 1b Trial of IFx-Hu2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)NASDAQ:CWBRCohBar Inc
31/05/202322h51Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NASDAQ:CWBRCohBar Inc
30/05/202314h05GlobeNewswire Inc.Morphogenesis, Inc. and CohBar, Inc. Announce Acceptance of Abstract for Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:CWBRCohBar Inc
23/05/202313h56Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NASDAQ:CWBRCohBar Inc
23/05/202313h30GlobeNewswire Inc.CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer ImmunotherapyNASDAQ:CWBRCohBar Inc
15/05/202314h33Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:CWBRCohBar Inc
28/04/202315h01Edgar (US Regulatory)Amended Annual Report (10-k/a)NASDAQ:CWBRCohBar Inc
09/03/202322h12Edgar (US Regulatory)Annual Report (10-k)NASDAQ:CWBRCohBar Inc
08/02/202315h01Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:CWBRCohBar Inc
08/02/202315h01Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:CWBRCohBar Inc
07/12/202215h00Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CWBRCohBar Inc
17/11/202214h31Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CWBRCohBar Inc
08/11/202222h46Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:CWBRCohBar Inc
 Showing the most relevant articles for your search:NASDAQ:CWBR

Kürzlich von Ihnen besucht

BOV
MOAR3Q
MONT ARANHA ON
AMEX
DNN
Denison Mines
FX
NOKUSD
NOK vs US Dollar
TG
L60
Highlight Event and Ente...
FX
CHFNZD
CHF vs NZD
EU
NSC000000057
Dummy 5 Utp
EU
EAS2P
Docdata Nv
EU
MLMR
Monumental Residence Soc...
NYSE
ANF
Abercrombie and Fitch
NYSE
JNY
Jones Apparel
AMEX
CVM
Cel Sci
EU
DSY
Dassault Systemes
NYSE
EGO
Eldorado Gold
NYSE
PAR
PAR Technology
FX
PLNCHF
PLN vs CHF
NYSE
ENZ
Enzo Biochem
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten